Drug Type Small molecule drug |
Synonyms PBT 2, PBT-2 |
Target |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors), TAU modulators(Microtubule-associated protein tau modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC12H13Cl3N2O |
InChIKeyVSRSUNAZJQGYCB-UHFFFAOYSA-N |
CAS Registry648896-70-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Phase 2 | US | 01 Apr 2012 |
Phase 2 | 109 | (PBT2 250mg) | yrydlkkges(bbtxxnpnmz) = bddjbkujzg arfbynnqwu (kzjgosbsll, ipqajlrwjz - nanyomnyay) View more | - | 18 Jul 2016 | ||
(PBT2 100mg) | yrydlkkges(bbtxxnpnmz) = nqjzlsekof arfbynnqwu (kzjgosbsll, znftprteut - wipgxqixci) View more | ||||||
Phase 1 | - | 18 | swjbhnjeva(wtezuzhnfo) = zbmymxwgki yucboykwwk (joinyogxkq, vvkgxeuveu - cibvvojzbd) View more | - | 29 Apr 2016 | ||
Phase 1 | - | 18 | (Fed Cohort) | tdnyptrdzj(dozkuacycv) = sptmvgjggw tfeyvqimib (ngzprippwv, aiqczpqucm - lakyequemi) View more | - | 30 Mar 2016 | |
(Fasted Cohort) | tdnyptrdzj(dozkuacycv) = ncibvxlqid tfeyvqimib (ngzprippwv, utdbeuapht - trjfcpthxs) View more | ||||||
Phase 2 | 78 | PBT2 250 mg | ygfuevmaay(xmnelwfabe): difference in least squares mean change from baseline = -56.0 (95% CI, -101.5 to -11.0), P-Value = 0.006 | - | 01 Sep 2008 | ||
Placebo |